Last10K.com

Acasti Pharma Inc. (ACST) SEC Filing 8-K Material Event for the period ending Monday, May 8, 2023

SEC Filings

ACST Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ACST Annual Reports

ACST Quarterly Reports

ACST Corporate News

ACST Corporate News

ACST Merger Prospectus

Acasti Pharma Inc.

HISTORY TOOLS
CIK: 1444192 Ticker: ACST

View differences made from one to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information
Ticker: ACST
CIK: 1444192
Form Type: 8-K Corporate News
Accession Number: 0000950170-23-021346
Submitted to the SEC: Thu May 11 2023 4:50:23 PM EST
Accepted by the SEC: Thu May 11 2023
Period: Monday, May 8, 2023
Industry: Pharmaceutical Preparations
Events:
  1. Event for Officers
  2. Other Events

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/acst/0000950170-23-021346.htm